Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

Bank of America Securities analyst Jason Gerberry reiterated a Buy rating on Jazz Pharmaceuticals (JAZZ – Research Report) today and set a ...

Dublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus on neuroscience and oncology. JAZZ is a Zacks Rank #2 (Buy) stock, with a Value Style Score of A ...

Atria Investments Inc lifted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 19.5% during the fourth ...

Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Dublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus on neuroscience and oncology. JAZZ is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Nasdaq-listed GW is in line for $220 ...

Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...